lysophosphatidic acid has been researched along with Cardiotoxicity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, X; Guo, S; Jiang, C; Li, X; Liu, J; Ma, Y; Mei, S; Sun, N; Tang, K; Wang, X; Zhao, D | 1 |
1 other study(ies) available for lysophosphatidic acid and Cardiotoxicity
| Article | Year |
|---|---|
18:0 Lyso PC, a natural product with potential PPAR-γ agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db/db mice.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Biological Products; Cardiotoxicity; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Fatty Acids; Heart; Hypoglycemic Agents; Lipids; Liver; Lysophospholipids; Male; Medicine, Chinese Traditional; Mice; Molecular Docking Simulation; PPAR gamma; Rosiglitazone | 2021 |